View
3
Download
0
Category
Preview:
Citation preview
NB! The dashed borders around
the logo graphics are not visible
in Show view or on print
Insert new picture
1. Delete old picture
2. Select picture placeholder
3. Insert picture from
ImageShopper
4. Use Image Tools to pan,
crop, zoom and compress
Insert new picture
1. Delete old picture
2. Select picture placeholder
3. Insert picture from
ImageShopper
4. Use Image Tools to pan,
crop, zoom and compress
Bringing psoriasis into the light Geneva Pharma Forum 9 May 2014 Kim Kjøller, Senior Vice President, Global Development, LEO Pharma
14 May 2014
p. 01
Insert picture
1. Delete old picture
2. Select picture placeholder
3. Insert picture from
ImageShopper
4. Use Image Tools to pan,
crop, zoom and compress
Psoriasis: A chronic, non-communicable disease affecting over 125 million people worldwide
Psoriasis appears on the skin, most often as thickened, red, scaly patches that often itch and may bleed. It is a non-contagious, chronic, inflammatory disease that can be both painful and disabling.ii
More people with psoriasis need better access to the medical care and appropriate solutions for either their psoriasis or for the psychosocial issues they may face as a result of their psoriasis.ii
People with psoriasis report feeling embarrassed and helpless due to their condition.ii
14 May, 2014
p. 02
Picture: Nestle FO et al. N Engl J Med 2009;361:496-509 i "Facts about Psoriasis." Ed. Catie Coman. National Psoriasis Foundation, 2012. Web. 19 Dec. 2012. <http://www.psoriasis.org/document.doc?id=1492>. ii "Psoriasis and Mental Health Issue Brief." National Psoriasis Foundation, Jan. 2012. Web. 11 Dec. 2012 <http://www.psoriasis.org/document.doc?id=350>.
People with severe psoriasis die four years younger, on average, than people without the disease. iii
As many as 30% of people with psoriasis will be diagnosed with
psoriatic arthritis, a specific form of arthritis that is painful and debilitating and causes joint damage.ii
Psoriasis increases the risk of developing diabetes,
independent of factors such as weight, hypertension and high cholesterol.iv
One study showed that psoriasis patients have a 44% increased
risk of suicidal thoughts, suicide attempts or completed suicides compared to the general population.v Another study showed that almost 10% of psoriasis patients surveyed reported a wish to be dead.vi
Burden of Disease How psoriasis affects patients
iii Gelfand JM, et al. Arch of Dermatol. 2007 Dec;143(12):1493-9. iv Neimann AL, et al. J Am Acad Dermatol. 2006;55(5):829-35. vKurd Sk, et al. Arch of Dermatol. 2010 Aug:146(8)891-5. vi Gupta MA, Gupta AK. Br J Dermatol 1998;139:846-50.
To add pre-formatted
bullet text please use the
Increase/Decrease Indent
buttons found in the
Top-PowerPoint menu
Psoriasis Pipeline Projects Topicals
p. 04
14 May, 2014
Phase 1
Phase 2
Phase 3
Pre-registration
AN-2898 Anacor Pharmaceuticals
LP-001-09 LAILA
Pharmaceuticals
Pc4 Case Western Reserve
University
BYK-321084 Takeda Pharma
SHP-141 Shape
Pharmaceuticals
ENN-01 Ennar Pharrma
SOM-0606 Ennar Pharrma
BCT194 Novartis
Aganirsen Gene Signal
AN-2728 Anacor Pharmaceuticals
Apo805K1 ApoPharma
BFH-772 Novartis
CT-327 Creabilis
Cyclosporine Advancell
DPS-151 DermsPsor
E-6201 Eisai
IDP 118 Valeant
LAS-41004 Almirall
PH 10 IMCOR
Ruxolitinib Incyte Corp
Tofacitinib Pfizer Valrubicin
Valderm
Nia-114 Niadyne Pharma
Clobetasol proprionate
Foamix
AKVANO Lipidor
DLX-105 Delenex
Therapeutics AS-101 BioMas Auranofin
Viralytics
MOL4249 Moleculin
DD 25 Fortuderm
Triamcinolone acetonide
Nuvo Research
Methotrexate MediQuest
Betamethasone Valerate 0.12%
Foamix
TU-2100 Tammarking
AM-001 DermAct
Benvitimod Stiefel
Pefcalcitol Maruho
Tacrolimus Novaliq
DFD01 Promius Pharma
Ulobetasol Therapeutics
Unknown formulation Spray/Foam Microemulsion Lotion Cream Ointment Gel
4 - 6 years to market
2 - 4 years to market
1 year to market
Tazarotene + betamethasone
Chongging Huapont Pharma
*Source: Cortellis and ADIS
To add pre-formatted
bullet text please use the
Increase/Decrease Indent
buttons found in the
Top-PowerPoint menu
Psoriasis Pipeline Projects Biologics
14 May 2014
p. 05
Phase 1
Phase 2
Phase 3
Pre-registration
BTT-1023 BioTie Therapies
CJM Novartis
AGM-811 Amgen
BI-655066 Boehringer Ingelheim
18C3 X-Biotech
AbGn-168 AbGenomics
Intravenous Subcutaneous Injectable
ASKP1240 Astellas Pharma
Tregalizumab AbbVie
Guselkumab Janssen Biotech
IMO-3100 Idera Pharmaceuticals
Inecalcitol Hybrigenics
IMO-8400 Idera Pharmaceuticals
4 - 6 years to market
3 - 4 years to market
1 year to market
Brodalumab Amgen Inc
Ixekizumab Eli Lilly & Co.
KHK-4827 Amgen
Tildrakizumab Schering-Plough
Corp/Merck
Secukinumab Novartis
Etanercept Biosimilar Sandoz
*Source: Cortellis and ADIS
Adalimumab Biosimilar Sandoz
To add pre-formatted
bullet text please use the
Increase/Decrease Indent
buttons found in the
Top-PowerPoint menu
Psoriasis Pipeline Projects Orals
14 May 2014
p. 06
Phase 1
Phase 2
Phase 3 Pre-registration
4 - 6 years to market
2 - 4 years to market
1 year to market
*Source: Cortellis and ADIS
Otezla® (Apremilast) Celgene
CM-2489 TorreyPines/CalciMedica
CT-1578 Cell Theraputics
PRX-167700 Proximagen Group
Trichuris suis ova Coronado Biosciences
XP-23829 Xenoport Inc.
Aminopterin Syntrix Biosystems
ASP 015K Astellas Pharma
Dimethyl fumarate Forward Pharma
Baricitinib Incyte Corp/Eli Lilly Ponesimod
Actelion Ltd SRT 2104 Sirtris Pharma, a GSK company
VB-201 VBL Therapeutics
Erlotinib OSI Pharmaceuticals
CH-1504 Chelsea Therapeutics
FX-125L Boehringer Ingelheim
HBP-347 Hy BioPharma
MT-1303 Mitsubishi Tanabe Pharma
INCB-039110 Incyte Corp
LLL 3348 Lupin
CF-101 Can-Fite BioPharma
Tofacitinib Pfizer
LAS 41008 Almirall
Voclosporin Aurina Pharmaceuticals
Inecalcitol Hybrigenics
To view drawing guides
1. Right-click outside slide and
select ’Grid and Guides...’
2. Check ’Display drawing
guides on screen’
3. Select ’OK’
NB! The dashed borders around
the logo graphics are not visible
in Show view or on print
Insert new picture
1. Delete old picture
2. Select picture placeholder
3. Insert picture from
ImageShopper
4. Use Image Tools to pan,
crop, zoom and compress
14 May 2014
p. 07
“A strong programmatic and multidisciplinary approach to
disease management that includes the coordination of care with
specialists and other health care professionals, as well as
consideration of patients’ needs and preferences are central to
the management of all non-communicable diseases including
psoriasis.”
- WHO Psoriasis Report, 2013
Giving patients control of their disease
Insert picture
1. Delete old picture
2. Select picture placeholder
3. Insert picture from
ImageShopper
4. Use Image Tools to pan,
crop, zoom and compress
We go beyond products to offer complete care solutions
• Patient support services empowers people to take control of their skin condition
• Our care offerings aim to deliver precise and personalised information to patients – across all therapy areas
Data collection What gaps do we need to fill?
14 May, 2014
p. 09
Example of interactive disease atlas
NB! The dashed borders around
the logo graphics are not visible
in Show view or on print
Insert new picture
1. Delete old picture
2. Select picture placeholder
3. Insert picture from
ImageShopper
4. Use Image Tools to pan,
crop, zoom and compress
Insert new picture
1. Delete old picture
2. Select picture placeholder
3. Insert picture from
ImageShopper
4. Use Image Tools to pan,
crop, zoom and compress
WHO Psoriasis Resolution
14 May 2014
p. 010
The goal of getting the WHO psoriasis resolution adopted is a necessary challenge that must be met in order to create a better environment for psoriasis patients to lessen the stigma and discrimination they endure.
Recommended